Table 3 Characteristics and outcomes of retrieved trials for outcome “Takotsubo syndrome”
From: Cardiac complications in patients with COVID-19: a systematic review
Takotsubo syndrome | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors | Age (years) all patients | Age (years) treatment group | Age (years) control group | Sex (M/F)+ | Cardiological comorbidities (n° pts) | Other comorbidities (n° pts) | COVID-19 severity | Type of CMP (n° pts or cases-controls) | Troponin T or I values – BNP or NT-proBNP values π | EF value (n° pts)π | Other no cardiac complications (n° pts) | Outcome (n° pts or cases-controls) |
Dabbagh et al. [18] | 63+ | NA | NA | 0/1 | Dilated cardiomyopathy (1) Chronic heart failure (1) | NA | NA | Takotsubo syndrome (1) | Tn I 2410 ng/L+ | 40% | NA | Discharge (1) |
Dweck et al. [24] | 62 (52–71)§ | 64 (53–73)§ | 60 (51–69)§ | 844/365 | Hypertension (445) Diabetes (233) Ischemic heart disease (167) Heart failure (113) Valvular disease (80) | NA | Patients in critical care setting (ICU, coronary care unit, emergency room, cardiac catheter laboratory) | Takotsubo syndrome (19) | NA | NA | NA | NA |
Meyer et al. [34] | 83+ | NA | NA | 0/1 | Hypertension (1) | NA | NA | Takotsubo syndrome (1) | TnT 1142 ng/L+ | NA | Pneumonia (1) | Discharge (1) |
Sala et al. [40] | 43+ | NA | NA | 0/1 | NA | NA | NA | Inverted Takotsubo syndrome (1) | TnT 135 ng/L+ NT-proBNP 512 pg/mL+ | EF 43% | NA | NA |
Solano-Lopez et al. [45] | 50+ | NA | NA | 1/0 | NA | Mediastinal tumor (1) | NA | Inverted Takotsubo syndrome (1) | TnI 64 pg/ml+ BNP 790 pg/ml+ | NA | Pneumonia (1) | Discharge (1) |
Stӧbe et al. | 64 ± 19.1° | 71 ± 15.2° | 41 ± 11.8° | 14/4 | Hypertension (13) Paroxysmal atrial fibrillation (4) Coronary artery disease (2) Dyslipidemia (4) Diabetes (5) Stroke (3) | Chronic kidney disease (7) COPD (1) | Severe symptoms: mechanical ventilation needed | Inverted Takotsubo (7/1) | TnT 36 ± 23 pg/ml° NT-proBNP 1724 ± 1058 pg/ml° | 62 ± 6.5%° (18) | Mechanical ventilation (14) | NA |